MEDP vs VCYT: fair value comparison
Medpace Holdings, Inc. and Veracyte, Inc. · Updated 2026-08-31
MEDP currently screens as overvalued while VCYT screens as fairly valued. Within Healthcare, VCYT currently sits closer to the top of our discount ranking. VCYT carries the stronger quality grade.
| MEDP | VCYT | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $573.29 | $44.85 |
| 12-month range | $417.54–$594.02 | $30.11–$59.85 |
| Sector rank | #90 of 113 Healthcare | #85 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: MEDP fair value analysis · VCYT fair value analysis